drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous chimeric antigen receptor T-cell therapy engineered to target CD33 and CD123 on AML cells, inducing T-cell activation and cytotoxic killing with in vivo expansion/persistence.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express chimeric antigen receptors that bind CD33 and CD123 on AML cells. Antigen engagement triggers T‑cell activation, cytokine release, proliferation, and perforin/granzyme‑mediated cytotoxic killing, with in vivo expansion and persistence enabling ongoing clearance of CD33/CD123‑positive leukemic cells.
drug_name
CD123/CD33 CAR T cells (EB-BH2025)
nct_id_drug_ref
NCT06420063